Life sciences encompass diverse subdomains, of which the most renowned ones are TechBio, BioPharma, Omics, and SynBio. Semiconductor technologies have transformative potential in each of these subdomains in different ways.
• TechBio refers to the developers of technology platforms to discover and deliver therapeutics. Typically, these platforms are not regulated, but marketed for research purposes, which allows for rapid market entry, either as products or services for BioPharma. Furthermore, the pricing of these platforms is not constrained by reimbursement, and their target customers often display a high willingness to pay.
Semiconductors play a critical role in enabling the miniaturization and automation of high-throughput experimentation platforms in TechBio, such as lab-on-a-chip devices, biosensors, and edge computing systems used for real-time data capture and analysis. The integration of advanced chips facilitates faster iteration cycles, greater sensitivity, and the deployment of AI models at the point of experimentation.
• BioPharma refers to the developers of actual therapeutics. Note that the lines between BioPharma and TechBio are sometimes blurred.
BioPharma comprises BioTech and Pharma:
BioTech (short for biotechnology) companies are typically smaller, research-focused firms that develop new therapeutics. They often specialize in exploring treatment hypotheses at the early stage of development and often lack largescale development, manufacturing or commercialization infrastructure.
Pharma (short for pharmaceutical) companies are usually large, established firms with full capabilities to develop, manufacture, and market drugs globally. In practice, many new drug candidates originate in BioTech or TechBio startups, which then partner with or are acquired by Pharma to finance expensive late-stage trials, production and commercialization.
In BioPharma, semiconductor technologies are accelerating both discovery and development by powering for example computational drug design, molecular and atomic simulations, and AI-driven target validation. Custom silicon and domain-specific chips, such as those optimized for molecular dynamics or neural network inference, enable breakthroughs in both speed and cost-effectiveness across the preclinical and clinical pipeline.
• Omics refers to the comprehensive analyses of information stored and communicated in biological systems. The analytes can be very diverse, and comprise e.g., an organism’s DNA sequences (e.g., genomics), the modifications of the bases of their DNA (epigenomics), how actively the DNA is being used to make RNA (transcriptomics) which can then be used to synthesize proteins (proteomics). Cells and system level functions can also be analyzed by the cellular communities within an environment (microbiomics) and their by-products during operation (metabolomics). Some studies focus specifically on sugars (glycomics), fats (lipidomics) or ions (ionomics). If different analytes are analysed in parallel, it is referred to as multiomics.
Just like in the TechBio subdomain, most of these platforms are not regulated (allowing for rapid market entry) and pricing is often not reimbursement constrained.
Semiconductors are at the heart of Omics platforms, enabling both the sensor technologies used for data acquisition (e.g., CMOS sensors in sequencers) and the high-throughput computing needed to process, analyze, and interpret petabyte-scale biological datasets. Specialized hardware accelerators are becoming essential to handle the complexity and speed demanded by multi-omics integration.
SynBio refers to synthetic biology, i.e. the engineering and use of new biological systems. These biological systems can either be used directly (e.g., in the case of synthetic genes or synthetic genomes), or be used to produce products that are of high value (e.g., specific proteins, lipids, flavors and other specialty ingredients). It is a rapidly growing segment with VC investments exceeding $12 billion in 2024.
In SynBio, semiconductor technologies are enabling the scaling of design-buildtest-learn cycles through the use of programmable automation, microfluidics, and integrated biosensor systems. One of the advantages of the miniaturization is the possibility for reduced reagent consumption while expanding the number of different building block combinations that can be generated. Moreover, chips used for digital synthesis, real-time bio-production monitoring, and AI-driven metabolic ngineering are becoming central to improving both precision and yield.